Ex vivo isolated human vessel perfusion system for the design and assessment of nanomedicines targeted to the endothelium. Issue 2 (28th January 2020)

• Record Type: Journal Article
• Authors: Lysyy, Taras; Bracaglia, Laura G.; Qin, Lingfeng; Albert, Claire; Pober, Jordan S.; Tellides, George; Saltzman, W. Mark; Tietjen, Gregory T.
• Is Part Of: Bioengineering & translational medicine. Volume 5:Issue 2(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-28
• Subjects: clinical translation -- drug delivery systems -- endothelial cell targeting -- ex vivo perfusion -- molecularly targeted therapies -- nanoparticle accumulation -- nanotechnology; Bioengineering -- Periodicals; Drug development -- Periodicals; Drugs -- Testing -- Periodicals; 660.6
• DOI: 10.1002/btm2.10154
• Languages: English
• ISSNs: 2380-6761

Abstract

Abstract: Endothelial cells play a central role in the process of inflammation. Their biologic relevance, as well as their accessibility to IV injected therapeutics, make them a strong candidate for treatment with molecularly‐targeted nanomedicines. Typically, the properties of targeted nanomedicines are first optimized in vitro in cell culture and then in vivo in rodent models. While cultured cells are readily available for study, results obtained from isolated cells can lack relevance to more complex in vivo environments. On the other hand, the quantitative assays needed to determine the impact of nanoparticle design on targeting efficacy are difficult to perform in animal models. Moreover, results from animal models often translate poorly to human systems. To address the need for an improved testing platform, we developed an isolated vessel perfusion system to enable dynamic and quantitative study of vascular‐targeted nanomedicines in readily obtainable human vessels isolated from umbilical cords or placenta. We show that this platform technology enables the evaluation of parameters that are critical to targeting efficacy (including flow rate, selection of targeting molecule, and temperature). Furthermore, biologic replicates can be easily produced by evaluating multiple vessel segments from the same human donor in independent, modular chambers. The chambers can also be adapted to house vessels of a variety of sizes, allowing for the subsequent study of vessel segments in vivo following transplantation into immunodeficient mice. We believe this perfusion system can help to address long‐standing issues in endothelial targeted nanomedicines and thereby enable more effective clinical translation.